John Docherty is president of Helix BioPharma in Toronto, Canada. Mr. Docherty joined the company in 1999. He has degrees in toxicology and pharmacology and a comprehensive background in pharmaceutical product and corporate development. At Helix, Mr. Docherty has been instrumental in developing the company's lead product candidate, Topical Interferon Alpha-2b, in addition to supporting growing investor and media relations initiatives. Before he was named president, Mr. Docherty was vice president of corporate development.